Breathing Labs
Home
How To Start
Products
Breathing+ Package
Toys Package
Q&A
Login

Covid19

20Oct

Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital

Posted by: admin Categories: Covid19
Comments Off on Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital

Remdesivir is the only antiviral approved for lower respiratory tract infection produced by SARS-CoV-2. The main objective of this study was to determine the mortality rate, readmissions, mean hospital stay, need for higher levels of oxygen support, and adverse effect-induced abandonment rate in hospitalized patients diagnosed with COVID-19 and treated with remdesivir (RDSV). The secondary […]

Read more
15Oct

Ivermectin is placed right under remdesivir on the NIH treatment list and they even dose ivermectin for covid. This just shows that before the coordinated attack it was totally greenlit for use for covid – The Donald

Posted by: admin Categories: Covid19
Comments Off on Ivermectin is placed right under remdesivir on the NIH treatment list and they even dose ivermectin for covid. This just shows that before the coordinated attack it was totally greenlit for use for covid – The Donald

Disclaimer: I am not a doctor and this is not medical advice Most tubes that have the plunger rated in pounds dose at a .2mg / kg. The box the paste comes in should list the dosage level on it somewhere. The ones i’ve had experience with typically have a notch for every 50lb. In […]

Read more
15Oct

Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda

Posted by: admin Categories: Covid19
Comments Off on Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda

The newly emerging Kappa, Delta, and Lambda SARS-CoV-2 variants are worrisome, characterized with the double mutations E484Q/L452R, T478K/L452R, and F490S/L452Q, respectively, in their receptor binding domains (RBDs) of the spike proteins. As revealed in crystal structures, most of these residues (e.g., 452 and 484 in RBDs) are not in direct contact with interfacial residues in […]

Read more
15Oct

Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial

Posted by: admin Categories: Covid19
Comments Off on Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial

To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with COVID-19. Patients were randomly assigned at a 1:1 ratio to receive either remdesivir (200 mg on the first day followed by 100 mg daily for the next 9 days […]

Read more
15Oct

Prediction of in-hospital mortality with machine learning for COVID-19 patients treated with steroid and Remdesivir

Posted by: admin Categories: Covid19
Comments Off on Prediction of in-hospital mortality with machine learning for COVID-19 patients treated with steroid and Remdesivir

Background: We aimed to create the prediction model of in-hospital mortality using machine learning methods for patients with COVID-19 treated with steroid and remdesivir. Study design and setting: We reviewed 1,571 hospitalized patients with laboratory confirmed COVID-19 from the Mount Sinai Health System treated with both steroid and remdesivir. The important variables associated with in-hospital […]

Read more
13Oct

23615309

Posted by: admin Categories: Covid19
Comments Off on 23615309

%PDF-1.7 % 1 0 obj >/Metadata 5 0 R/Outlines 2 0 R/Pages 3 0 R/StructTreeRoot 4 0 R/Type/Catalog/ViewerPreferences 6 0 R>> endobj 5 0 obj >stream 2021-10-13T16:41:42-07:00 2021-10-10T16:46:32-07:00 2021-10-13T16:41:42-07:00 Appligent AppendPDF Pro 5.5 uuid:7f973a56-b26c-11b2-0a00-782dad000000 uuid:86d0638e-1dd2-11b2-0a00-6a00783ab5ff application/pdf 23615309 kakinoki yasutaka Microsoft® Word for Microsoft 365 AppendPDF Pro 5.5 Linux Kernel 2.6 64bit Oct 2 2014 Library 10.1.0 […]

Read more
13Oct

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults – Full Text View

Posted by: admin Categories: Covid19
Comments Off on A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults – Full Text View

The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants. The secondary objectives of the study are: To evaluate the safety and tolerability of repeated SC injections of casirivimab+imdevimab in the study population To characterize concentrations of casirivimab and […]

Read more
9Oct

JCI – Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Posted by: admin Categories: Covid19
Comments Off on JCI – Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Clinical MedicineVirology Free access | 10.1172/JCI151697 Colin F. Pawlowski,2 John C. O’Horo,1 Lori L. Arndt,3 Richard F. Arndt,3 Sarah J. Bell,1 Dennis M. Bierle,1 Raymund Razonable #JCI – #bamlanivimab associates with reduced #hospitalization, ICU admission and mortality in >4600 high-risk patients with mild to moderate #COVID19 ⁦@jclinicalinvest⁩ […]

Read more
8Oct

One Mayo Clinic doctor breaks down the best treatment for COVID-19

Posted by: admin Categories: Covid19
Comments Off on One Mayo Clinic doctor breaks down the best treatment for COVID-19

ROCHESTER, Minn. – Since the beginning of the pandemic, medical experts have worked hard to develop treatments for patients with COVID-19. From personal protective equipment and social distancing to monoclonal antibody therapy, there are so many treatments out there for COVID-19. All of which have been approved for use by the FDA. There has only […]

Read more
6Oct

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Posted by: admin Categories: Covid19
Comments Off on Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

To the Editor O’Brien et al. report that the combination of casirivimab and imdevimab (REGEN-COV) reduced the risk of symptomatic Covid-19 by 81.4% among persons exposed to SARS-CoV-2.1 However, we question the decision to communicate the effect size almost exclusively with the use of the relative risk reduction, calculated as 1 minus the relative risk. […]

Read more
6Oct

Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial

Posted by: admin Categories: Covid19
Comments Off on Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial

Purpose: Trials of tocilizumab in patients with severe COVID-19 pneumonia have demonstrated mixed results, and the role of tocilizumab in combination with other treatments is uncertain. Here we evaluated whether tocilizumab plus remdesivir provides greater benefit than remdesivir alone in patients with severe COVID-19 pneumonia. Methods: This randomized, double-blind, placebo-controlled, multicenter trial included patients hospitalized […]

Read more
5Oct

Monoclonal Antibody Treatment Combination Reduces Hospitalization Among High-Risk COVID-19 Patients – COVID-19

Posted by: admin Categories: Covid19
Comments Off on Monoclonal Antibody Treatment Combination Reduces Hospitalization Among High-Risk COVID-19 Patients – COVID-19

In an observational study, researchers have reported that the combination of casirivimab and imdevimab – two monoclonal antibody treatments under Food and Drug Administration emergency use authorization – can keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. In the study that enrolled nearly 1,400 patients from Mayo Clinic (Rochester, […]

Read more
5Oct

3 nabbed for illegal sale of COVID drugs

Posted by: admin Categories: Covid19
Comments Off on 3 nabbed for illegal sale of COVID drugs

Marc Jayson Cayabyab – The Philippine Star October 6, 2021 | 12:00am MANILA, Philippines — Three persons were arrested by the National Bureau of Investigation (NBI) in Pasay for allegedly selling medicine used to treat COVID-19. Karen Amero, Ronaldo Ceriola and Erickson Soriano were arrested in a sting launched by the NBI Anti-Graft Division last […]

Read more
3Oct

Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period

Posted by: admin Categories: Covid19
Comments Off on Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period

Background: Remdesivir (RDV) was approved for treatment of coronavirus disease 2019 (COVID-19), in May 2020 under US Food and Drug Administration emergency use authorization (EUA). Clinical outcomes related to RDV use in hospitalized patients during the EUA period are not well described. Methods: We conducted a retrospective study of patients who received RDV under EUA. […]

Read more
3Oct

Probing remdesivir nucleotide analogue insertion to SARS-CoV-2 RNA dependent RNA polymerase in viral replication

Posted by: admin Categories: Covid19
Comments Off on Probing remdesivir nucleotide analogue insertion to SARS-CoV-2 RNA dependent RNA polymerase in viral replication

Abstract Remdesivir (RDV) prodrug can be metabolized into a triphosphate form nucleotide analogue (RDV-TP) to bind and insert into the active site of viral RNA dependent RNA polymerase (RdRp) to further… Many UC-authored scholarly publications are freely available on this site because of the UC’s open access policies. Let us know how this access is […]

Read more
2Oct

Casirivimab and Imdevimab Benefits Hospitalized Seronegative COVID-19 Patients

Posted by: admin Categories: Covid19
Comments Off on Casirivimab and Imdevimab Benefits Hospitalized Seronegative COVID-19 Patients

Combination monoclonal antibodies casirivimab and imdevimab was associated with a significant reduction in viral load among hospitalized, seronegative patients with COVID-19 who required low flow or no supplemental oxygen, according to findings from a late-breaking abstract presented at IDWeek 2021. Presented by author Eleftherios Mylonakis, MD, PhD, Professor of Medicine & Molecular Microbiology and Immunology […]

Read more
2Oct

solar panels: CBIC notifies GST hike on green gear including solar panels

Posted by: admin Categories: Covid19
Comments Off on solar panels: CBIC notifies GST hike on green gear including solar panels

The Central Board of Indirect Taxes and Customs (CBIC) notified changes in the Goods and Services Tax (GST) rates for a host of products with effect from Friday, including solar modules, fruit-based aerated drinks, medicines and drugs. Renewable energy devices including solar panels and modules, bio-gas plants, solar power generators, windmills, solar lamps, tidal waves […]

Read more
1Oct

Resultados positivos en ensayos con monoclonales a pacientes hospitalizados

Posted by: admin Categories: Covid19
Comments Off on Resultados positivos en ensayos con monoclonales a pacientes hospitalizados

La farmacéutica suiza Roche informó hoy de que el tratamiento anticovid con anticuerpos monoclonales que comercializa junto a la estadounidense Regeneron reduce de forma significativa la carga viral de los pacientes hospitalizados en cuestión de una semana. Los ensayos en segunda y tercera fase llevados a cabo por la firma así lo confirman, lo que […]

Read more
30Sep

Roche: Phase 2/3 Trial of Covid-19 Treatment Ronapreve Met Primary Endpoint

Posted by: admin Categories: Covid19
Comments Off on Roche: Phase 2/3 Trial of Covid-19 Treatment Ronapreve Met Primary Endpoint

By Olivia Bugault Roche Holding AG said Thursday that its Phase 2/3 trial of Covid-19 treatment Ronapreve met its primary endpoint. Results from the trial show that Ronapreve, which is a combination of two antibodies, casirivimab and imdevimab, “significantly” reduces the viral load within seven days in patients who have been hospitalized with Covid-19, the […]

Read more
30Sep

Remdesivir Reduces Mortality in Some Hospitalized COVID-19 Patients

Posted by: admin Categories: Covid19
Comments Off on Remdesivir Reduces Mortality in Some Hospitalized COVID-19 Patients

Remdesivir (RDV) treatment in patients hospitalized with COVID-19 has evolved. The injectable therapy was given a Food and Drug Administration (FDA) Emergency Use Authorization in May 2020 to aid hospitals when they were badly in need of therapies. And almost a year ago, the FDA approved it for adults and children 12 and older who […]

Read more
« Older posts
Newer posts »